Paul Reider - 20 Mar 2023 Form 3 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Chief Commercial Officer
Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Paul Reider
Issuer symbol
CHRS
Transactions as of
20 Mar 2023
Net transactions value
$0
Form type
3
Filing time
28 Mar 2023, 18:48:19 UTC
Next filing
04 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CHRS Common Stock 89,504 20 Mar 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CHRS Stock Option (Right to Buy) 20 Mar 2023 Common Stock 125,000 $14.76 Direct F1
holding CHRS Stock Option (Right to Buy) 20 Mar 2023 Common Stock 40,000 $17.06 Direct F2
holding CHRS Stock Option (Right to Buy) 20 Mar 2023 Common Stock 37,500 $15.94 Direct F3
holding CHRS Stock Option (Right to Buy) 20 Mar 2023 Common Stock 80,000 $9.87 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 25% of the total number of shares subject to the option on the one year anniversary measured from March 22, 2021 and 1/48th of the total shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F2 The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from December 13, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F3 The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F4 The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney